For research use only. Not for therapeutic Use.
Vulpinic acid, a lichen metabolite, decreases H2O2-induced ROS production, oxidative stress and oxidative stress-related damages in human umbilical vein endothelial cells (HUVEC). Vulpinic acid is active against staphylococci, enterococci, and anaerobic bacteria.Vulpinic acid has the potential for atherosclerosis research[1][2].
| Catalog Number | R000484 |
| CAS Number | 521-52-8 |
| Synonyms | methyl (2E)-2-(3-hydroxy-5-oxo-4-phenylfuran-2-ylidene)-2-phenylacetate |
| Molecular Formula | C19H14O5 |
| Purity | ≥95% |
| InChI | InChI=1S/C19H14O5/c1-23-18(21)15(13-10-6-3-7-11-13)17-16(20)14(19(22)24-17)12-8-4-2-5-9-12/h2-11,20H,1H3/b17-15+ |
| InChIKey | OMZRMXULWNMRAE-BMRADRMJSA-N |
| SMILES | COC(=O)C(=C1C(=C(C(=O)O1)C2=CC=CC=C2)O)C3=CC=CC=C3 |
| Reference | [1]. E Sahin, et al. Vulpinic acid, a lichen metabolite, emerges as a potential drug candidate in the therapy of oxidative stress-related diseases, such as atherosclerosis. Hum Exp Toxicol. 2019 Jun;38(6):675-684. [2]. M Lauterwein, et al. In vitro activities of the lichen secondary metabolites vulpinic acid, (+)-usnic acid, and (-)-usnic acid against aerobic and anaerobic microorganisms. Antimicrob Agents Chemother. 1995 Nov;39(11):2541-3. |
